Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_provenance.
- NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_assertion description "[Methotrexate (MTX), 5-florouracil (5-Fu), and cisplatin (CDDP) are commonly used for breast carcinoma treatment in clinics; however, patients with HER2/neu overexpression exhibit resistance to these anticancer drugs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_provenance.
- NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_assertion evidence source_evidence_literature NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_provenance.
- NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_assertion SIO_000772 17885815 NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_provenance.
- NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_assertion wasDerivedFrom befree-20140225 NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_provenance.
- NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_assertion wasGeneratedBy ECO_0000203 NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_provenance.
- befree-20140225 importedOn "2014-02-25" NP208885.RACmhAMDnR7KgEbBqMaz9oBYgXQOUErHzEkwsJ3tzl200130_provenance.